| Product Code: ETC6188188 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The pharyngitis market in Australia is shaped by seasonal infection patterns and demand for both over-the-counter and prescription treatments. Viral pharyngitis is common, but concerns over bacterial strains like streptococcus drive diagnostic testing and antibiotic use.
The pharyngitis market in Australia is seeing a steady trend driven by seasonal flu outbreaks, rising antibiotic resistance concerns, and increased awareness regarding proper diagnosis and treatment. While traditional antibiotics remain widely used, there is a growing interest in non-antibiotic treatments, including herbal and lozenge-based remedies. Diagnostic advancements enabling rapid identification of bacterial vs. viral infections are also influencing treatment patterns.
The pharyngitis market in Australia struggles with differentiating between viral and bacterial infections, leading to overprescription of antibiotics. Public health campaigns and antimicrobial resistance concerns have also influenced treatment protocols, creating uncertainty in therapeutic demand.
Investments in the pharyngitis market are primarily shaped by national immunization and antimicrobial stewardship programs. These policies stimulate research and product development for new treatment options while regulating over-the-counter access to antibiotics, ensuring a sustainable market environment.
Policies affecting the pharyngitis market are tied to broader infectious disease management strategies and antibiotic stewardship programs. The Australia government, through agencies like the National Prescribing Service (NPS) and Australia Commission on Safety and Quality in Health Care, promotes rational use of antibiotics and diagnostic tools for pharyngitis. Additionally, reimbursement for treatment under Medicare drives consistent clinical management.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Pharyngitis Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Pharyngitis Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Pharyngitis Market - Industry Life Cycle |
3.4 Australia Pharyngitis Market - Porter's Five Forces |
3.5 Australia Pharyngitis Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.6 Australia Pharyngitis Market Revenues & Volume Share, By Mode of Delivery, 2021 & 2031F |
3.7 Australia Pharyngitis Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Australia Pharyngitis Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness about the importance of early detection and treatment of pharyngitis |
4.2.2 Growing prevalence of bacterial infections leading to pharyngitis |
4.2.3 Advancements in healthcare infrastructure and technology for accurate diagnosis and treatment |
4.3 Market Restraints |
4.3.1 Rising healthcare costs impacting access to pharyngitis treatment |
4.3.2 Antibiotic resistance leading to challenges in treating bacterial pharyngitis |
4.3.3 Lack of standardization in clinical guidelines for pharyngitis diagnosis and management |
5 Australia Pharyngitis Market Trends |
6 Australia Pharyngitis Market, By Types |
6.1 Australia Pharyngitis Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 Australia Pharyngitis Market Revenues & Volume, By Drug Class, 2021- 2031F |
6.1.3 Australia Pharyngitis Market Revenues & Volume, By Beta Lactams, 2021- 2031F |
6.1.4 Australia Pharyngitis Market Revenues & Volume, By Macrolides, 2021- 2031F |
6.1.5 Australia Pharyngitis Market Revenues & Volume, By Cephalosporins, 2021- 2031F |
6.1.6 Australia Pharyngitis Market Revenues & Volume, By Fluoroquinolones, 2021- 2031F |
6.1.7 Australia Pharyngitis Market Revenues & Volume, By Tetracycline, 2021- 2031F |
6.1.8 Australia Pharyngitis Market Revenues & Volume, By Reusable, 2021- 2031F |
6.2 Australia Pharyngitis Market, By Mode of Delivery |
6.2.1 Overview and Analysis |
6.2.2 Australia Pharyngitis Market Revenues & Volume, By Oral, 2021- 2031F |
6.2.3 Australia Pharyngitis Market Revenues & Volume, By Intravenous, 2021- 2031F |
6.2.4 Australia Pharyngitis Market Revenues & Volume, By Intramuscular, 2021- 2031F |
6.3 Australia Pharyngitis Market, By Distribution Channel |
6.3.1 Overview and Analysis |
6.3.2 Australia Pharyngitis Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.3.3 Australia Pharyngitis Market Revenues & Volume, By Retail Pharmacies & Drug Stores, 2021- 2031F |
6.3.4 Australia Pharyngitis Market Revenues & Volume, By Online Pharmacies, 2021- 2031F |
7 Australia Pharyngitis Market Import-Export Trade Statistics |
7.1 Australia Pharyngitis Market Export to Major Countries |
7.2 Australia Pharyngitis Market Imports from Major Countries |
8 Australia Pharyngitis Market Key Performance Indicators |
8.1 Rate of pharyngitis cases diagnosed at an early stage |
8.2 Adoption rate of non-antibiotic treatment options for pharyngitis |
8.3 Patient satisfaction with pharyngitis treatment outcomes |
9 Australia Pharyngitis Market - Opportunity Assessment |
9.1 Australia Pharyngitis Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.2 Australia Pharyngitis Market Opportunity Assessment, By Mode of Delivery, 2021 & 2031F |
9.3 Australia Pharyngitis Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Australia Pharyngitis Market - Competitive Landscape |
10.1 Australia Pharyngitis Market Revenue Share, By Companies, 2024 |
10.2 Australia Pharyngitis Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |